Central EU committee makes case for faster EU drug approval process
The EU Committee ENVI recommends that the EU Commission expands its collaboration with the EMA for the faster approval of medicines, concerning the EU's pharmaceutical strategy.
BY PETER THOMSEN eu correspondent for Watch medier, translated by daniel pedersen
With a world-spanning health crisis behind it, and with its ambition of strengthening the health preparedness on the horizon, providing a better framework for the drug approval process in the EU is needed. This is the recommendation from one of the European Parliament's central committees, ENVI, for the EU's future pharmaceutical strategy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
